SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Persson Camilla 1976 )
 

Search: WFRF:(Persson Camilla 1976 ) > (2020-2023) > Selection, characte...

  • Mortensen, AnjaUppsala University,Karolinska Institute,Uppsala universitet,Cancerprecisionsmedicin,Science for Life Laboratory, SciLifeLab,Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. (author)

Selection, characterization and in vivo evaluation of novel CD44v6-targeting antibodies for targeted molecular radiotherapy

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • Springer Nature,2023
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:kth-340841
  • https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-340841URI
  • https://doi.org/10.1038/s41598-023-47891-2DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-521802URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:154651316URI
  • https://lup.lub.lu.se/record/05b3aba5-b10e-4ae2-892e-0b4363272988URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • QC 20231218
  • Molecular radiotherapy combines the advantages of systemic administration of highly specific antibodies or peptides and the localized potency of ionizing radiation. A potential target for molecular radiotherapy is the cell surface antigen CD44v6, which is overexpressed in numerous cancers, with limited expression in normal tissues. The aim of the present study was to generate and characterize a panel of human anti-CD44v6 antibodies and identify a suitable candidate for future use in molecular radiotherapy of CD44v6-expressing cancers. Binders were first isolated from large synthetic phage display libraries containing human scFv and Fab antibody fragments. The antibodies were extensively analyzed through in vitro investigations of binding kinetics, affinity, off-target binding, and cell binding. Lead candidates were further subjected to in vivo biodistribution studies in mice bearing anaplastic thyroid cancer xenografts that express high levels of CD44v6. Additionally, antigen-dependent tumor uptake of the lead candidate was verified in additional xenograft models with varying levels of target expression. Interestingly, although only small differences were observed among the top antibody candidates in vitro, significant differences in tumor uptake and retention were uncovered in in vivo experiments. A high-affinity anti-CD44v6 lead drug candidate was identified, mAb UU-40, which exhibited favorable target binding properties and in vivo distribution. In conclusion, a panel of human anti-CD44v6 antibodies was successfully generated and characterized in this study. Through comprehensive evaluation, mAb UU-40 was identified as a promising lead candidate for future molecular radiotherapy of CD44v6-expressing cancers due to its high affinity, excellent target binding properties, and desirable in vivo distribution characteristics.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Berglund, HannaUppsala University,Uppsala universitet,Cancerprecisionsmedicin,Science for Life Laboratory, SciLifeLab(Swepub:uu)hanbe377 (author)
  • Segerström, LovaUppsala University,Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)loseg226 (author)
  • Walle, M.Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Science for Life Laboratory (SciLifeLab)(Swepub:lu)immu-mwe (author)
  • Hofström, CamillaKTH Royal Institute of Technology,KTH,Science for Life Laboratory, SciLifeLab,Läkemedelsutveckling,Karolinska Inst, Drug Discovery & Dev Platform, Stockholm, Sweden.;KTH Royal Inst Technol, Dept Prot Sci, Stockholm, Sweden.,Science for Life Laboratory (SciLifeLab)(Swepub:kth)u12237py (author)
  • Persson, HelenaKTH Royal Institute of Technology,KTH,Science for Life Laboratory, SciLifeLab,Läkemedelsutveckling,Karolinska Inst, Drug Discovery & Dev Platform, Stockholm, Sweden.;KTH Royal Inst Technol, Dept Prot Sci, Stockholm, Sweden.,Science for Life Laboratory (SciLifeLab)(Swepub:kth)u1l700sh (author)
  • Nygren, Per-Åke,1961-KTH Royal Institute of Technology,KTH,Science for Life Laboratory, SciLifeLab,Läkemedelsutveckling,Drug Discovery and Development Platform, Science for Life Laboratory (SciLifeLab), Stockholm, Sweden.;Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.(Swepub:kth)u1zhverl (author)
  • Nilvebrant, Johan,1982-KTH Royal Institute of Technology,KTH,Proteinteknologi,Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden,KTH Royal Inst Technol, Dept Prot Sci, Stockholm, Sweden.(Swepub:kth)u17j1dcn (author)
  • Frejd, Fredrik Y.Uppsala University,Uppsala universitet,Cancerprecisionsmedicin,Science for Life Laboratory, SciLifeLab(Swepub:uu)freni195 (author)
  • Nestor, Marika,1976-Uppsala University,Uppsala universitet,Cancerprecisionsmedicin,Science for Life Laboratory, SciLifeLab(Swepub:uu)manes424 (author)
  • Uppsala universitetCancerprecisionsmedicin (creator_code:org_t)

Related titles

  • In:Scientific Reports: Springer Nature13:12045-2322

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view